Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypoglycemia (Diabetic) Clear all

Conditions: Diabetes Mellitus
Interventions: Pulsatile IV insulin therapy, Effects of Pulsatile IV Insulin on Cognitive functions; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin]); Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets; Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Diabetes, Hypoglycemia, Renal Dysfunction, Insulin Dosing
Interventions: Not listed
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 99 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperglycaemia (Diabetic)
Interventions: Dichloroacetate, Placebo oral capsule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, With Complications
Interventions: Pulsatile IV Insulin, Effects of Pulsatile IV Insulin on Diabetic Retinopathy; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Diabetic Neuropathy
Interventions: Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 20 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions: 40% Dextrose gel; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 0 Hours to 1 Hour
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Allogeneic Islets of Langerhans, hOKT3γ1 (Ala-Ala); Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Hyperglycemia, Hypoglycemia (Diabetic)
Interventions: Sensing Device and Tedlar Bags; Device
Lead sponsor: Indiana University; Other
Eligibility: 7 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, With Complications
Interventions: Effect of Pulsatile IV Insulin on diabetic neuropathy; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions: Routine/prescribed exogenous insulin dose; Drug
Lead sponsor: Rachel Miller; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions: Islet Cell Transplant; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin; Biological · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Hypoglycemia
Interventions: 13C-MRS procedure/Acetate infusion, Continuous glucose monitoring; Other · Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • New Orleans, Louisiana

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
Interventions: Cholecalciferol, Omega 3 fatty acid; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 6 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: DKA
Interventions: Insulin Glargine; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Diabetes, Hypoglycemia
Interventions: BHT-3021, BHT-Placebo; Drug
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more

Conditions: Pregnancy, Gestational Diabetes Mellitus, Class A2, Neonatal Hypoglycemia
Interventions: Blood sugar check every 2 hours, Blood sugar check every 4 hours; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Falls Church, Virginia

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Escondido, California • Atlanta, Georgia + 1 more

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine; Biological · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus
Interventions: Effect of Pulsatile IV insulin on diabetic pt blood markers, Effect of Pulsatile IV Insulin on blood markers; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Brain Neoplasms, Intracranial Aneurysm
Interventions: Insulin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Efficacy of Islet After Kidney Transplantation

Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus

Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

Miniaturized Breath-based Sensor for the Detection of Hypo- and Hyperglycemia

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

Intrapartum Glycemic Control in GDMA2

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes

Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia